Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
BioFlorida ConferenceBioFlorida Conference
Not Confirmed
Not Confirmed
18-20 November, 2024
Not Confirmed
Not Confirmed
19-21 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
BioFlorida ConferenceBioFlorida Conference
Industry Trade Show
Not Confirmed
18-20 November, 2024
Industry Trade Show
Not Confirmed
19-21 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities
04 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/04/2973913/0/en/Arvinas-to-Participate-in-Upcoming-Investor-Conferences.html
30 Oct 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/10/30/2971572/0/en/Arvinas-Reports-Third-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html
22 Oct 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/10/22/2967321/0/en/Arvinas-Gives-Back-to-Local-Greater-New-Haven-Community-in-Third-Annual-Impact-Day.html
21 Oct 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/10/21/2966055/0/en/Arvinas-to-Report-Third-Quarter-2024-Financial-Results-and-Provide-Corporate-Update-and-Host-Webcast-on-Wednesday-October-30-2024.html
29 Aug 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/08/29/2937672/0/en/Arvinas-to-Participate-in-Upcoming-Investor-Conferences.html
30 Jul 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/07/30/2920865/0/en/Arvinas-Reports-Second-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html
Details:
ARV-471 (vepdegestrant) is an investigational PROTAC protein degrader designed to target and degrade the estrogen receptor. It is being evaluated for the treatment of ER+/HER2- breast cancer.
Lead Product(s): Vepdegestrant,Palbociclib
Therapeutic Area: Oncology Brand Name: ARV-471
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2024
Lead Product(s) : Vepdegestrant,Palbociclib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Not Applicable
Deal Type : Not Applicable
Arvinas and Pfizer Updated Clinical Data from Phase 1b of Vepdegestrant with Palbociclib
Details : ARV-471 (vepdegestrant) is an investigational PROTAC protein degrader designed to target and degrade the estrogen receptor. It is being evaluated for the treatment of ER+/HER2- breast cancer.
Brand Name : ARV-471
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 16, 2024
Details:
Novartis obtains worldwide development & commercialization rights to ARV-766, Arvinas’ 2nd-generation PROTAC androgen receptor degrader for prostate cancer, including its preclinical AR-V7 program.
Lead Product(s): Luxdegalutamide,Abiraterone Acetate
Therapeutic Area: Oncology Brand Name: ARV-766
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: Novartis Pharmaceuticals Corporation
Deal Size: $1,160.0 million Upfront Cash: $150.0 million
Deal Type: Licensing Agreement April 11, 2024
Lead Product(s) : Luxdegalutamide,Abiraterone Acetate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Novartis Pharmaceuticals Corporation
Deal Size : $1,160.0 million
Deal Type : Licensing Agreement
Arvinas Partners with Novartis On Global License for PROTAC® ARV-766
Details : Novartis obtains worldwide development & commercialization rights to ARV-766, Arvinas’ 2nd-generation PROTAC androgen receptor degrader for prostate cancer, including its preclinical AR-V7 program.
Brand Name : ARV-766
Molecule Type : Small molecule
Upfront Cash : $150.0 million
April 11, 2024
Details:
ARV-102 is a novel oral PROTAC® protein degrader designed to cross the blood-brain barrier and target LRRK2. It is being evaluated for parkinson’s disease and progressive supranuclear palsy.
Lead Product(s): ARV-102
Therapeutic Area: Neurology Brand Name: ARV-102
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Arvinas Announces First-in-Human Dosing of ARV-102, a PROTAC for Neurodegenerative Disease
Details : ARV-102 is a novel oral PROTAC® protein degrader designed to cross the blood-brain barrier and target LRRK2. It is being evaluated for parkinson’s disease and progressive supranuclear palsy.
Brand Name : ARV-102
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 20, 2024
Details:
ARV-471 (vepdegestrant) is an oral bioavailable PROTAC protein degrader designed to target & degrade the estrogen receptor, currently in phase 3 trials for ER+/HER2- breast cancer treatment.
Lead Product(s): Vepdegestrant
Therapeutic Area: Oncology Brand Name: ARV-471
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 06, 2024
Lead Product(s) : Vepdegestrant
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Not Applicable
Deal Type : Not Applicable
Arvinas and Pfizer’s Vepdegestrant Receives Fda Fast Track Designation for Treatment
Details : ARV-471 (vepdegestrant) is an oral bioavailable PROTAC protein degrader designed to target & degrade the estrogen receptor, currently in phase 3 trials for ER+/HER2- breast cancer treatment.
Brand Name : ARV-471
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 06, 2024
Details:
Arvinas expects to use net proceeds to advance its clinical development programs and preclinical pipeline, including ARV-471 (vepdegestrant), an investigational orally bioavailable PROTAC® protein degrader.
Lead Product(s): Vepdegestrant
Therapeutic Area: Oncology Brand Name: ARV-471
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: BofA Securities
Deal Size: $350.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement November 27, 2023
Lead Product(s) : Vepdegestrant
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : BofA Securities
Deal Size : $350.0 million
Deal Type : Private Placement
Arvinas Announces Oversubscribed $350 Million Private Placement
Details : Arvinas expects to use net proceeds to advance its clinical development programs and preclinical pipeline, including ARV-471 (vepdegestrant), an investigational orally bioavailable PROTAC® protein degrader.
Brand Name : ARV-471
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 27, 2023
Details:
ARV-471 (vepdegestrant) is an investigational, orally bioavailable PROTAC® protein degrader designed to specifically target and degrade the estrogen receptor for the treatment of patients with early and locally advanced breast cancer.
Lead Product(s): Vepdegestrant
Therapeutic Area: Oncology Brand Name: ARV-471
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2023
Lead Product(s) : Vepdegestrant
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ARV-471 (vepdegestrant) is an investigational, orally bioavailable PROTAC® protein degrader designed to specifically target and degrade the estrogen receptor for the treatment of patients with early and locally advanced breast cancer.
Brand Name : ARV-471
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 31, 2023
Details:
The collaboration aims to evaluate the novel combination of CT7001 (samuraciclib), an oral, first-in-class inhibitor of CDK7, and Arvinas’ ARV-471 (vepdegestrant), an investigational oral PROTAC® estrogen receptor protein degrader being developed in metastatic breast cancer.
Lead Product(s): Samuraciclib,Fulvestrant
Therapeutic Area: Oncology Brand Name: CT7001
Study Phase: PreclinicalProduct Type: Small molecule
Recipient: Carrick Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 06, 2023
Lead Product(s) : Samuraciclib,Fulvestrant
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Carrick Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims to evaluate the novel combination of CT7001 (samuraciclib), an oral, first-in-class inhibitor of CDK7, and Arvinas’ ARV-471 (vepdegestrant), an investigational oral PROTAC® estrogen receptor protein degrader being developed in m...
Brand Name : CT7001
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 06, 2023
Details:
ARV-766 is an investigational orally bioavailable PROTAC® protein degrader designed to degrade all clinically relevant resistance-driving point mutations of the androgen receptor (AR) and which being investigated forLate-line mCRPC.
Lead Product(s): Luxdegalutamide
Therapeutic Area: Oncology Brand Name: ARV-766
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2023
Lead Product(s) : Luxdegalutamide
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ARV-766 is an investigational orally bioavailable PROTAC® protein degrader designed to degrade all clinically relevant resistance-driving point mutations of the androgen receptor (AR) and which being investigated forLate-line mCRPC.
Brand Name : ARV-766
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 08, 2023
Details:
ARV-471 is an investigational, orally-bioavailable PROTAC® protein degrader designed to specifically target and degrade the estrogen receptor (ER) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer.
Lead Product(s): ARV-471,Palbociclib
Therapeutic Area: Oncology Brand Name: ARV-471
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 22, 2022
Lead Product(s) : ARV-471,Palbociclib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ARV-471 is an investigational, orally-bioavailable PROTAC® protein degrader designed to specifically target and degrade the estrogen receptor (ER) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer.
Brand Name : ARV-471
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 22, 2022
Details:
Initial goal of collaboration is to develop FoundationOne® liquid CDx as a companion diagnostic for Bavdegalutamide (ARV-110), Arvinas’ investigational Androgen receptor-targeting PROTAC® protein degrader.
Lead Product(s): Bavdegalutamide
Therapeutic Area: Oncology Brand Name: ARV-110
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: Foundation Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 05, 2022
Lead Product(s) : Bavdegalutamide
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Foundation Medicine
Deal Size : Undisclosed
Deal Type : Collaboration
Foundation Medicine Announces Strategic Collaboration with Arvinas
Details : Initial goal of collaboration is to develop FoundationOne® liquid CDx as a companion diagnostic for Bavdegalutamide (ARV-110), Arvinas’ investigational Androgen receptor-targeting PROTAC® protein degrader.
Brand Name : ARV-110
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 05, 2022
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?